First‐in‐Human Phase I Study of Merestinib, an Oral Multikinase Inhibitor, in Patients with Advanced Cancer

BACKGROUND. The purpose of this nonrandomized, open‐label, phase I study (NCT01285037) was to evaluate the safety and tolerability of merestinib, an oral antiproliferative and antiangiogenic kinase inhibitor, and to determine a recommended phase II dose and schedule for patients with advanced cancer...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Oncologist
Hlavní autoři: He, Aiwu Ruth, Cohen, Roger B., Denlinger, Crystal S., Sama, Ashwin, Birnbaum, Ariel, Hwang, Jimmy, Sato, Takami, Lewis, Nancy, Mynderse, Michelle, Niland, Michele, Giles, Jennifer, Wallin, Johan, Moser, Brian, Zhang, Wei, Walgren, Richard, Plimack, Elizabeth R.
Médium: Artigo
Jazyk:Inglês
Vydáno: John Wiley & Sons, Inc. 2019
Témata:
New Drug Development and Clinical Pharmacology
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6738318/
https://ncbi.nlm.nih.gov/pubmed/30833489
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2018-0411
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky